Science & Enterprise subscription

Follow us on Twitter

  • Bio-engineers developed a process using the gene editing technique Crispr to design gel materials with properties a… https://t.co/EQx2U5NDVv
    about 7 hours ago
  • New post on Science and Enterprise: Crispr Deployed for Programmable Smart Hydrogels https://t.co/n9KDIpvZOs #Science #Business
    about 7 hours ago
  • New sponsored post on Science and Enterprise: https://t.co/67quzkiZng Business Practices to Keep Retail Competitive with Online
    about 14 hours ago
  • An academic-industry collaboration is creating a non-invasive technique to detect rupture-prone plaque build-ups in… https://t.co/U6v6tBF4PA
    about 1 day ago
  • New post on Science and Enterprise: Math Model to Gauge Heart Attack Risk from Plaques https://t.co/7BIPROFhpv #Science #Business
    about 1 day ago

Please share Science & Enterprise

New Medical Technologies Investment Fund Raises $110M

Wall Street signs

(A. Kotok)

19 August 2014. HealthQuest Capital, a spin-off investment firm, says it raised $110 million for funding in technology-based start-ups serving the health care industry. The company was spun off from Sofinnova Ventures in Menlo Park, California and founded by Garheng Kong, a Sofinnova general partner.

HealthQuest plans to invest in companies developing medical devices, diagnostics, patient-care products, mobile health, and health care information technologies. The company says it is particularly interested in new enterprises that can show quantifiable benefits in terms of patient care and health care economics. “It is our strong belief,” says the HealthQuest Web site, “that the winning formula for emerging companies in health care is to have a strong story in both these areas.”

The company aims to target newer enterprises in North America, but those beyond the initial start-up stage, where investments can help grow revenues and scale-up operations for the marketplace. Pre-launch businesses will be considered, if commercial operations are imminent and can show evidence of likely market adoption. Investments will generally be in the range  of $2 to $4 million, for companies with capital needs less than $20 million to reach profitability.

HealthQuest started last year, and its portfolio already includes Castle Biosciences developing molecular diagnostics for cancer and First Aid Shot Therapy, commercializing over-the-counter medications as single liquid doses of 40 milliliters or 1.35 ounces (A shot glass holds about 45 milliliters or 1.5 ounces.). A third portfolio company, Vestagen Technical Technologies in Orlando, Florida, develops antimicrobial and other specialized textiles with a process licensed from researchers in Switzerland.

HealthQuest first aimed at raising $50 million in its first fund, but the response from investors was particularly strong, thus the fund remained open until reaching $110 million. The company expects to make a total of 12 investments from that fund. HealthQuest remains affiliated with Sofinnova Ventures that provides back-office support.

Read more:

*     *     *

Please share Science & Enterprise ...
error

Comments are closed.